The Board of Bactiguard Holding AB (publ) (“Bactiguard” or the “Company”) has today, pursuant to authorisations granted by the annual general meeting on 19 May 2026, resolved on a directed issue and immediate repurchase of 715,000 Class C shares. The measures are intended to ensure the Company’s ability to deliver shares to participants in the share-based long-term incentive plan 2026 (“LTIP 2026”) adopted by the annual general meeting if, and to the extent that, the relevant performance conditions are satisfied during the plan’s performance measurement period.
The annual general meeting resolved to adopt LTIP 2026 for the CEO, other members of the management team, managers and certain key employees at Bactiguard. In connection therewith, the annual general meeting resolved to authorise the board of directors to resolve on directed new issue of redeemable and convertible Class C shares and on repurchases of Class C shares for the purpose of securing delivery of shares under the program.
The Board has today resolved to exercise these authorisations by issuing 715,000 Class C shares and subsequently repurchasing all Class C shares in accordance with the terms of LTIP 2026. Skandinaviska Enskilda Banken AB subscribed for all issued Class C shares at a subscription price corresponding to the quota value, entailing an increase of the Company’s share capital by SEK 17,875. All Class C shares have subsequently been repurchased by Bactiguard for an amount per share corresponding to the quota value.
The Class C shares will be converted into Class B shares in connection with the delivery of Class B shares to participants in accordance with the terms of LTIP 2026 as approved by the AGM.
For further information, please contact:
Patrick Bach, CFO +46 761 295 911
About Bactiguard
Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas where infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access. Bactiguard operates through license partnerships with leading global MedTech companies that apply the technology to their medical devices. The company also has a portfolio of wound management products. Bactiguard’s infection prevention solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine. Bactiguard is headquartered in Stockholm and is listed on Nasdaq Stockholm and is included in the Small-Cap segment. Read more about Bactiguard: www.bactiguard.com
